Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple myeloma: what's new.

B G Durie

    CA: a Cancer Journal for Clinicians
    |October 2, 2001
    PubMed
    Summary

    High-dose therapy with autologous stem cell transplant significantly improves outcomes for multiple myeloma patients, offering a potential cure. Newer treatments like thalidomide are enhancing remission rates and survival.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Immunologic Aspects of the Hematologic Neoplasms.

    Postgraduate medicine·2016
    Same author

    Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.

    Leukemia·2007
    Same author

    The epidemiology of multiple myeloma.

    Seminars in hematology·2001
    Same author

    RT-PCR amplicons in the plasma of multiple myeloma patients--clinical relevance and molecular pathology.

    Acta oncologica (Stockholm, Sweden)·2001
    Same author

    Re: Cell and molecular biology of simian virus 40: implications for human infections and disease.

    Journal of the National Cancer Institute·1999
    Same author

    Patient preferences for interferon alfa in multiple myeloma.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1997

    Area of Science:

    • Hematology
    • Oncology
    • Clinical Trials

    Background:

    • Conventional therapy for multiple myeloma yields low complete response rates (5%).
    • Recent clinical trials demonstrate improved outcomes with high-dose therapy and autologous hematopoietic stem cell transplant.
    • Median survival exceeds 5 years in patients undergoing this intensive treatment.

    Discussion:

    • Newer therapeutic strategies are enhancing treatment efficacy.
    • Potent induction regimens, including thalidomide and dexamethasone combinations, show promise.
    • These advancements are critical for improving patient survival and quality of life.

    Key Insights:

    • High-dose therapy with autologous stem cell transplant increases complete remission rates to 25-30%.
    • Thalidomide-based regimens are emerging as effective treatments for multiple myeloma.
    • Treatment advancements are shifting the prognosis for multiple myeloma patients.

    Outlook:

    • The potential for a cure for multiple myeloma is becoming increasingly attainable.
    • Continued research into novel therapeutic approaches is warranted.
    • Optimizing treatment protocols may lead to long-term disease remission and survival.

    Related Experiment Videos